AHF shares The Lancet’s concerns over use of Gilead’s Truvada as HIV prevention pill Today AIDS Healthcare Basis commented on an editorial published in the September 2011 issue of The Lancet Infectious Illnesses that raises problems about the usage of the HIV treatment medication Truvada, manufactured by Gilead Sciences Inc., as an HIV prevention pill or pre-exposure prophylaxis , agreeing with the publication’s public health issues fda website . In particular, the publication address the fact that HIV ‘treatment as avoidance’ has become common wisdom in the field. Major studies show that an HIV-infected person that is on treatment is certainly up to 96 percent less infectious and, therefore, significantly less likely to pass the virus to others.
She did it before it was fashionable,’ said Michael Weinstein, President of AIDS Healthcare Foundation. ‘She spoke truth to power on a number of problems, including chiding President Reagan for not saying the term AIDS rather than funding work on AIDS. Her corporation had no overhead, and it helped fund AHF and other organizations in LA. For her to say something and show her compassion transformed the game. The ads are also reminder that, though Ms. Taylor bravely stood up for folks coping with HIV/AIDS at an important moment in history, the AIDS epidemic is still not over and there remains much work to be achieved.